Technology News and Research

RSS

BioClinica third quarter service revenues increase 4.1% to $16.6 million

BioClinica, Inc., a global provider of clinical trial management and technology solutions, today announced its financial results for the third quarter and nine months ended September 30, 2011.

From Clario 9 Nov 2011

Study explores how telework may impact work exhaustion

If you work from home part of the week as a teleworker, does it help reduce work exhaustion caused by juggling work and family commitments? The answer may depend on the level of conflict you have between work and home and your ability to recharge your batteries adequately, according to Professor Timothy Golden, from the Rensselaer Polytechnic Institute in Troy, NY.

9 Nov 2011

Svelte initiates Rapamycin-eluting stent with bio-Eroding Carrier Technology implantation study

Svelte Medical Systems today announced treatment of the first patient in the DIRECT (Direct-on-a-wire Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study at Auckland City Hospital in Auckland, New Zealand.

9 Nov 2011

BioMimetic Therapeutics reports third quarter total revenues of $0.4M

BioMimetic Therapeutics, Inc., a biotechnology company specializing in the development and commercialization of innovative bioactive products to promote the healing of musculoskeletal injuries and diseases, today reported its financial results as of and for the three and nine months ended September 30, 2011.

9 Nov 2011

Salix third quarter total product revenue increases 81% to $146.2 million

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the third quarter ended September 30, 2011 and other business updates.

9 Nov 2011

BioTime third quarter revenue increases 40% to $1.1 million

BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.

9 Nov 2011

Health insurance exchanges generating controversy, even within GOP

A Wisconsin state senator blocking health care reform implementation in the state is calling on Gov. Scott Walker's administration to return a major federal grant to build information technology infrastructure for new health insurance exchanges. So far, though, it looks like Walker isn't listening. Wisconsin is the last GOP-led state holding onto its Early Innovator grant.

9 Nov 2011

Insmed third quarter revenues decrease to $0.4 million

Insmed Incorporated, a biopharmaceutical company, today reported financial results for the third quarter and nine-months ended September 30, 2011.

9 Nov 2011

Access partners to exploit CobaCyte and CobOral technology for targeted RNAi therapeutic delivery

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major player in RNAi industry to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

9 Nov 2011

Almac devises new test to detect likelihood of colon cancer recurring

Northern Ireland-based pharmaceutical development company Almac has devised a groundbreaking new test which can detect the likelihood of the recurrence of stage 2 colon cancer in patients who have undergone surgery.

9 Nov 2011

Fewer businesses take advantage of health tax credits

The Treasury Department says the number of small businesses taking a new tax credit set up in the 2010 health law is smaller than expected. Also, a report to be issued Thursday says the FDA should not be in charge of health information technology.

9 Nov 2011

Omega Protein third quarter revenues increase 28.1% to $71.7 million

Omega Protein Corporation, a nutritional ingredient company and the nation's leading vertically integrated producer of omega-3 fish oil and specialty fish meal products, today reported financial results for the third quarter ended September 30, 2011.

9 Nov 2011

University of Houston to enhance cancer research facilities

Thanks to almost $1 million in new funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the University of Houston (UH) will soon be enhancing its cancer research facilities.

9 Nov 2011

AcelRx reports revenue of $408,000 for third quarter 2011

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

Boston Scientific reports positive long-term data from PERSEUS clinical program

Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.

9 Nov 2011

Fluidigm third quarter total revenue increases 25% to $10.6 million

Fluidigm Corporation today announced its financial results for the third quarter ended September 30, 2011.

9 Nov 2011

Inova Labs secures $17.5M in Series B round of equity financing

Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive Pulmonary Disease (COPD) market, announced today that it has secured a Series B round of equity financing for up to $17.5M from an investment syndicate led by Latterell Venture Partners, based in San Francisco, Calif.

9 Nov 2011

ScreenCell, Transgenomic sign collaboration and distribution agreement for CTC technology

Transgenomic, Inc. and ScreenCell, a privately-held company, today announced the signing of a perpetual, worldwide collaboration and distribution agreement for ScreenCell's Isolation Devices and Dilution Buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

9 Nov 2011

DFINE closes $25 million round of equity financing

DFINE, Inc., the developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, announced today the closing of a $25 million round of equity financing.

9 Nov 2011

Bioject third quarter revenues increase to $3.1 million

Bioject Medical Technologies Inc., a leading developer of needle-free drug delivery systems, today reported financial results for the third quarter ended September 30, 2011.

8 Nov 2011